Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more
– Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.6 | -18.5714285714 | 14 | 14.72 | 11.08 | 716363 | 12.24010199 | CS |
| 4 | -0.76 | -6.25 | 12.16 | 14.72 | 11.08 | 466430 | 12.75221633 | CS |
| 12 | -2.44 | -17.6300578035 | 13.84 | 16.15 | 11.08 | 577616 | 13.29118466 | CS |
| 26 | -4.52 | -28.391959799 | 15.92 | 17.58 | 11.08 | 590491 | 13.96723414 | CS |
| 52 | 7.28 | 176.699029126 | 4.12 | 17.58 | 3.77 | 691351 | 12.200801 | CS |
| 156 | -17.9 | -61.0921501706 | 29.3 | 33.0635 | 3.35 | 429581 | 12.21706887 | CS |
| 260 | -12.62 | -52.5395503747 | 24.02 | 71.58 | 3.35 | 318948 | 16.40445594 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
